CHPA supports advancing modernization of USP's quality monographs, updating and improving the compendial test methods and establishing product standards which can provide an additional measure of safety for OTC products.
CHPA supports improving the compendial test methods and establishing product standards for levels of elemental impurities which can provide an additional measure of safety for OTC products.
Letter to Dr. Shawn Dressman regarding U.S. Pharmacopeia's Stimuli article: USP's Monographs in Support of FDA's OTC Monograph System: Modernization Opportunities.
CHPA takes this opportunity to respectfully express our opposition to SF 1166, a measure proposing to ban the sale of products containing triclosan in Minnesota.
CHPA takes this opportunity to respectfully express our opposition to proposed Ordinance #02013-1063, a measure proposing to ban the sale of products containing triclosan in the City of Chicago.
This report builds upon current insights with findings from a new survey which examines two important stakeholder groups and analyzes what drives these groups’ use and trust in OTC medicines.
To gain new insights on the issue of what drives trust in OTC medicines, Nielsen and IMS partnered to conduct surveys of consumers and healthcare providers to understand what leads both groups to trust OTC medicines.
